Archive for the 'Cancer' Category
Calistoga Pharmaceuticals Initiates First Oncology Clinical Trial Of Novel PI3K Delta Inhibitor, CAL-101
Calistoga Pharmaceuticals, Inc., a company committed to developing innovative medicines for the treatment of cancer and inflammatory diseases, announced the initiation of a Phase 1 clinical trial of its lead compound, CAL-101, a small molecule phosphoinositide-3 kinase (PI3K) delta inhibitor, in patients with hematologic cancer. “We at Calistoga are very pleased to be entering our first oncology trial.
Original post by Women’s Health / Gynecology News From Medical News Today
Elusive Target In Cancer Cells Targeted By Magnolia Compound
A natural compound from magnolia cones blocks a pathway for cancer growth that was previously considered “undruggable,” researchers have found. A laboratory led by Jack Arbiser, MD, PhD, at Emory University School of Medicine, has been studying the compound honokiol, found in Japanese and Chinese herbal medicines, since discovering its ability to inhibit tumor growth in mice in 2003.
Original post by Women’s Health / Gynecology News From Medical News Today
Cancer Drug Reformulation Featured In Prestigious Journal
Dr. Yuri Lvov, a professor of chemistry and T. Pipes endowed chair in micro and nanosystems at Louisiana Tech University, and Anshul Agarwal, a Louisiana Tech doctoral candidate in biomedical engineering feature their cancer drug reformulation work in the most recent issue of Pharma Focus Asia, one of the largest and most respected pharmaceutical science journals in the world.
Original post by Women’s Health / Gynecology News From Medical News Today
Researching Pyran-Based Anticancer Natural Products
Thomas E. Smith, associate professor of chemistry at Williams College, has been awarded a $217,710 three-year grant by the National Cancer Institute of the National Institute of Health (NIH) for “Asymmetric Methods for the Synthesis of Pyran-Based Anticancer Natural Products.” “This research is concerned with the development of new methods that will allow for the efficient preparation of anticancer compounds,” said Smith.
Original post by Women’s Health / Gynecology News From Medical News Today
Molecular Evidence Of The Independent Origin Of Multiple Wilms Tumors In A Case Of WAGR Syndrome
UroToday.com - A study by Dr. Uccini, et al., evaluated the molecular evidence of the independent origin of multiple Wilms tumors in a patient who has WAGR syndrome. The paper was a description of the procedure, technique and its results. They had one patient who was 1 year of age. that child developed two synchronous bilateral Wilms tumors that were resected by partial nephrectomy. Histologically, these tumors were fetal rhabdomyomatous nephroblastomas.
Original post by Women’s Health / Gynecology News From Medical News Today
Discovery Of Mechanism That Explains How Cancer Enzyme Winds Up On Ends Of Chromosomes
Human cancer cells divide and conquer. Unless physicians can control that division with surgery, chemotherapy or radiation, the wildly dividing cells will eventually destroy a person’s life. Researchers have known for some day that an enzyme called telomerase is crucial to cancer’s progress.
Original post by Women’s Health / Gynecology News From Medical News Today
BioAlliance Pharma Launches Loramyc(R) In The UK, Germany And Denmark
BioAlliance Pharma SA (Euronext Paris - BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announced the launch of its lead product Loramyc® on the British, German and Danish markets. “This simultaneous product launch in three European countries crowns the efforts of our teams and marks another concrete step in the internationalization of our business.
Original post by Women’s Health / Gynecology News From Medical News Today
